Canada: 2018 Mid-Year Highlights In Canadian Life Sciences IP

In this special mid-year edition, we take a look at the major highlights in Canadian life sciences and intellectual property law that we have reported on over the last six months, starting with one of the most closely-watched issues, the PMPRB amendments, presently under consideration.

1. Proposed PMPRB amendments under consideration, proposed guidance pending; litigation matters

Consultation on proposed Regulations Amending the Patented Medicines Regulations closed on February 15; consideration is ongoing. Potential changes to pricing criteria include expanding the list of comparator countries to twelve, but excluding the US and Switzerland, and taking into account pharmacoeconomic value. On December 11, the Patented Medicine Prices Review Board (PMPRB) released a scoping paper, and a steering committee will now consult on drafting new guidelines, expected to be released this fall (see June 25 Guidance Document). The proposed amendments contributed to Canada's appearance on the Office of the US Trade Representative's Priority Watch List.

Alexion's application for leave to appeal a decision dismissing its challenge to the constitutionality of certain PMPRB provisions of the Patent Act was dismissed on June 28. Two other court cases are pending: (i) the PMPRB's appeal in GALDERMA on the jurisdictional issue of whether an invention "pertains to" a medicine and (ii) Alexion's judicial review application of the Board's decision regarding SOLIRIS (eculizumab) on the use of the Board's Guidelines (scheduled for September).

2. Eight certificates of supplementary protection (CSPs) have issued

Certificates of supplementary protection (CSPs) provide an additional patent-like protection term, and are intended to partly compensate the innovator for the time required for research and obtaining regulatory approval in Canada. Canada's regime came into force on September 21, 2017. Earlier this year, we provided a chart comparing CSPs to European Supplementary Protection Certificates. Eight CSPs have issued to date.

3. Amended PMNOC Regulations: early procedural decisions, updated Health Canada guidance, 21 cases started

Substantial amendments to the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) came into force on September 21, 2017, followed by release of the Federal Court's practice notice. In March, two procedural decisions issued, finding: confidentiality rules cannot be varied until an action is commenced, and a motion to dismiss may be brought prior to completion of examinations for discovery. On May 11, Health Canada issued updated Guidance, including Patent Register eligibility of CSPs. To date, approximately 21 actions (regarding 14 products) have been started and 11 trials have been scheduled.

4. Biosimilars Update: Consultation on naming approaches; CADTH updates review process; REMICADE patent valid and infringed by INFLECTRA

We provided an update on biosimilars in our June issue, including on new biosimilar approvals (there are now 11 in total), ongoing litigation matters, the Canadian Agency for Drugs and Technologies in Health (CADTH)'s Environmental Scan, and aligned reviews between Health Canada and health technology assessment organizations. Further, there was a consultation on naming and CADTH revised its biosimilar review process. Finally, our most-read article this year related to the March 7 decision of the Federal Court finding a patent for a use of infliximab (Janssen's REMICADE) in combination with methotrexate for the treatment of rheumatoid arthritis was valid and infringed by Hospira's biosimilar INFLECTRA: Hospira v Kennedy Trust and Janssen, 2018 FC 259. Hospira's appeal is pending.

5. Cannabis Act passes in Canada

Bill C-45, the Cannabis Act, received Royal Assent on June 21, and adult use cannabis will be legal in Canada as of October 17. Final regulations to the Cannabis Act are expected soon, and will likely be similar to the proposals set out in the Proposed Approach to the Regulation of Cannabis: Summary of Comments Received During the Public Consultation.

6. Consultation on national pharmacare

On February 27, the creation of an Advisory Council on the Implementation of National Pharmacare (Council) was announced and on April 19, the Standing Committee on Health released a report advocating a national pharmacare program – a single payer universal publicly funded prescription drug coverage program for all Canadians. On June 20, the Council was launched, together with release of a Discussion Paper and the opening of a public consultation.

7. No section 8 liability for valid and infringed patent in NEXIUM proceedings; Teva succeeds in olanzapine section 8 appeal

On February 15, AstraZeneca was found not liable to Apotex for any section 8 damages relating to its esomeprazole magnesium product (a generic version of AstraZeneca's NEXIUM), as Apotex's claim would be fully offset by its liability for patent infringement in the but-for world: Apotex v AstraZeneca, 2018 FC 181. The Court separately held that AstraZeneca was entitled to a declaration of infringement in AstraZeneca's infringement action (following the Supreme Court of Canada decision striking down the promise doctrine), and in doing so, rejected Apotex's attempts to raise new grounds of invalidity.

On March 20, the Federal Court of Appeal dismissed Eli Lilly's appeal of a decision awarding $70 million in section 8 damages to Teva, relating to its lost olanzapine sales (a generic version of Eli Lilly's ZYPREXA), but granted Teva's cross-appeal seeking lost pipefill sales and an adjustment for under-reporting of sales. Eli Lilly has sought leave to appeal.

Finally, on April 25, the Quebec Superior Court declined to dismiss Apotex's claim under the Ontario Statute of Monopolies relating to amlodipine besylate (Pfizer's NORVASC), finding it has jurisdiction: Apotex c Pfizer, 2018 QCCS 1765.

8. Damages, accounting references: Teva's $19 million levofloxacin damages appeal dismissed; $61 million perindopril profits award against Apotex stands

On February 8, the Federal Court of Appeal dismissed Teva's appeal relating to Janssen's damages ($19 million) for infringement of Janssen's patent for levofloxacin (LEVAQUIN): Teva v Janssen, 2018 FCA 33, including affirming that Janssen US had standing to make a claim, i.e. it was not required to demonstrate that it had engaged in conduct in Canada that would otherwise amount to infringement. Teva has sought leave to appeal.

On March 28, Servier and ADIR were successful in the redetermination of the profits reference relating to perindopril (Servier's COVERSYL): the Federal Court again dismissed Apotex's non-infringing alternative defence, finding that Apotex would not have called on foreign third parties to manufacture perindopril to supply Apotex affiliates in the UK and Australia. The original $61 million profits award against Apotex was therefore re-affirmed: ADIR and Servier v Apotex, 2018 FC 346. Apotex has appealed.

Finally, the Federal Court of Appeal has confirmed that an infringer does not have the right to elect a patentee's remedy: Apotex v Bayer, 2018 FCA 32.

9. Health Canada updates: Strengthening post-marketing oversight

The Protecting Canadians from Unsafe Drugs Act (Vanessa's Law), which was approved on November 6, 2014, amended the Food and Drugs Act and granted the Minister of Health new post-marketing oversight powers over therapeutic products. We prepared a summary chart of the developments to date including: consultation on draft guidance governing public release of clinical information contained in drug submissions and medical device applications; a Notice of Intent to propose post-market amendments to the Medical Devices Regulations; new regulations governing powers to require assessments, tests and studies and notification of foreign incidents; new regulations governing post-market oversight over opioids; and proposed new regulations for hospital report of serious adverse drug reactions and medical device incidents. Other new guidance documents include: a consultation on potential changes to the Use of a Foreign-sourced Reference Product as a Canadian Reference Product Guidance; administrative processing of submissions; and reporting of adverse reactions.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions